Table 4.
Hematologic and nonhematologic treatment-emergent adverse events (TEAE)
| TEAE | Total, N = 20 |
|
|---|---|---|
| Any grade | Grade 3-4 | |
| Hematologic TEAEs∗ | ||
| Total patients with hematologic TEAE | 19 (95) | 19 (95) |
| Neutropenia | 17 (85) | 17 (85) |
| Thrombocytopenia | 16 (80) | 14 (70) |
| Anemia | 14 (70) | 11 (55) |
| Leukopenia | 11 (55) | 11 (55) |
| Lymphopenia | 6 (30) | 6 (30) |
| Nonhematologic TEAEs∗ | ||
| Metabolism and nutrition disorders | 17 (85) | 7 (35) |
| Hypomagnesemia | 7 (35) | 0 |
| Hypocalcemia | 6 (30) | 2 (10) |
| Hypophosphatemia | 6 (30) | 4 (20) |
| Gastrointestinal disorders | 11 (55) | 0 |
| Diarrhea | 7 (35) | 0 |
| Vomiting | 4 (20) | 0 |
| CRS and neurotoxicity | ||
| CRS | 12 (60) | 0 |
| ICANS | 4 (20) | 2 (10) |
| Other neurotoxicity† | 0 | 0 |
Data are n (%).
CRS, cytokine release syndrome; ICANS, immune effector cell–associated neurotoxicity syndrome.
∗
Reported in ≥20% of patients.
†
Other neurotoxicity includes parkinsonism.